- Home
- IMRX vs CNTX Comparison
IMRX vs CNTX Comparison
Compare IMRX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMRX | CNTX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 283.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMRX | CNTX |
|---|---|---|
| Price | $4.56 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $17.20 | $6.60 |
| AVG Volume (30 Days) | ★ 1.9M | 607.2K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.67 | $0.54 |
| 52 Week High | $10.08 | $3.62 |
Technical Indicators
Market Signals| Indicator | IMRX | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 42.48 |
| Support Level | N/A | $2.10 |
| Resistance Level | $5.47 | $2.54 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 10.71 | 15.46 |
Price Performance
Historical ComparisonAbout IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.